Meier C A, Dickstein B M, Ashizawa K, McClaskey J H, Muchmore P, Ransom S C, Menke J B, Hao E H, Usala S J, Bercu B B
Molecular, Cellular and Nutritional Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Mol Endocrinol. 1992 Feb;6(2):248-58. doi: 10.1210/mend.6.2.1569968.
Mutations in the gene encoding the human beta 1 T3 receptor (hTR beta 1) have been associated with generalized resistance to thyroid hormone (GRTH). We measured the T3-binding affinity and transcriptional regulatory capacity of the mutant hTR beta 1 from four unrelated kindreds with GRTH. These mutations are contained in different functional regions of the ligand-binding domain. The T3 affinity of the mutant receptors correlated well with the degree of impairment of their trans-activating function in a transient cotransfection system in HeLa cells; two mutant receptors with undetectable ligand affinity showed no transcriptional activity, whereas the two other mutants characterized by a 2- and 5-fold reduction in T3 affinity required 5- and 15-fold higher T3 concentrations for half-maximal activity in the cotransfection assay, respectively. All of the mutant hTR beta 1s were able to inhibit the function of transfected normal hTR beta 1 and endogenous retinoic acid receptor in activating a palindromic positive T3 response element (TRE). In the partially functional mutants this dominant negative effect could be completely reversed by increased T3 concentrations. The dominant negative potency did not depend on the type of TRE used; mutant hTR beta 1s were able to inhibit normal receptor function to the same degree on a dimer-permissive palindromic TRE as on a nondimer-permissive inverted repeat of two identical half-sites separated by five spacer bases. However, the dominant negative potency was dependent on the absolute amount of receptor expression vector transfected. The expression of normal and mutant hTR beta 1 was assessed by immunocytochemistry. The hTR beta 1 protein levels in HeLa cells paralleled the amount of transfected expression vector. Moreover, all the mutant receptors were properly expressed in the nuclei of the transfected cells. These data suggest that different mutations in the ligand-binding domain of the human hTR beta 1 result in a variable degree of functional impairment, which may partially explain the phenotypic differences between kindreds with GRTH. Our findings suggest that competition for binding to the TRE and possibly the binding of limiting accessory factors may be more important in mediating the dominant negative effect than the formation of normal/mutant T3 receptor dimers.
编码人β1甲状腺激素受体(hTRβ1)的基因突变与全身性甲状腺激素抵抗(GRTH)有关。我们测定了来自四个无亲缘关系的GRTH家系的突变型hTRβ1的T3结合亲和力和转录调控能力。这些突变存在于配体结合域的不同功能区域。在HeLa细胞的瞬时共转染系统中,突变型受体的T3亲和力与其反式激活功能的受损程度密切相关;两个检测不到配体亲和力的突变型受体没有转录活性,而另外两个T3亲和力分别降低2倍和5倍的突变体,在共转染实验中达到半数最大活性所需的T3浓度分别高5倍和15倍。所有突变型hTRβ1都能够抑制转染的正常hTRβ1和内源性视黄酸受体激活回文正向T3反应元件(TRE)的功能。在部分功能的突变体中,这种显性负效应可通过增加T3浓度完全逆转。显性负效应的强度不取决于所用TRE的类型;突变型hTRβ1在允许二聚体形成的回文TRE上抑制正常受体功能的程度与在由五个间隔碱基分隔的两个相同半位点的非二聚体允许的反向重复序列上相同。然而,显性负效应的强度取决于转染的受体表达载体的绝对量。通过免疫细胞化学评估正常和突变型hTRβ1的表达。HeLa细胞中的hTRβ1蛋白水平与转染的表达载体量平行。此外,所有突变型受体都在转染细胞的细胞核中正确表达。这些数据表明,人hTRβ1配体结合域的不同突变导致功能受损程度不同,这可能部分解释了GRTH家系之间的表型差异。我们的研究结果表明,在介导显性负效应方面,与TRE结合的竞争以及可能有限的辅助因子的结合可能比正常/突变型T3受体二聚体的形成更重要。